Furthermore, given the interplay between tumor-derived and stromal-derived chemokines, we propose that co-targeting of multiple chemokine pathways may be required in order to diminish multiple behavioral traits of aggressive PTEN-deficient prostate cancer cells. The gene discussed is PTEN; the disease is prostate cancer.